PHILADELPHIA - FORE Biotherapeutics today announced that the Company will be presenting at the 2024 Goldman Sachs 45th Annual Global Healthcare Conference.

The presentation will take place on Thursday, June 13, 2024, at 9:20-9:55 AM ET.

William Hinshaw, Chief Executive Officer, and Jeffrey Sacher, Interim Chief Financial Officer, will host and participate in one-on-one meetings. Please contact your Goldman Sachs salesperson or Argot Partners to schedule one-on-one meetings with the management team.

About FORE Biotherapeutics

Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company's lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor with manageable clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. The Fore Bio research and development team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options.


Email: moc.srentraptogra@oiBeroF

Tel: 2091.006.212

(C) 2024 Electronic News Publishing, source ENP Newswire